Literature DB >> 3038302

Activation of human monocyte tumoricidal activity by C-reactive protein.

B P Barna, K James, S D Deodhar.   

Abstract

We examined the effect of purified human C-reactive protein (CRP) on induction of human peripheral blood monocyte (Mo)-mediated cytotoxicity (CTX) and oxidative metabolism. Exposure of Mo to acute phase serum levels of CRP in vitro resulted in dose-dependent expression of CTX against human tumor cell lines. Nonneoplastic human fibroblasts and glial cells were not affected by CRP-exposed Mo, and treatment of Mo monolayers with anti-Leu 11b (a natural killer marker) and complement did not abrogate or diminish CTX. Tumoricidal activity was observed after 20-44 h of Mo exposure to CRP, and after 48-72 h of coculture with radiolabeled target tumor cells. Mo exposed to CRP for 48 h also demonstrated elevated superoxide anion production when challenged with phorbol myristate acetate. Unlike CTX induced by lipopolysaccharide, CRP-induced CTX was completely inhibited by preincubation of CRP with phosphorylcholine, a CRP ligand, at a concentration of 5.5 molecules phosphorylcholine per molecule CRP. Further, when Mo medium (which contained 5% human AB serum) was preincubated with immobilized CRP, exposure of Mo to CRP in such medium did not result in CTX. In contrast, LPS-induced CTX was not affected. CRP-induced Mo CTX was observed, however, when Mo were exposed to CRP in medium preincubated with phosphorylcholine-treated immobilized CRP, suggesting that an active serum component which complexed with CRP was not removed. These findings indicate that one of the functions of the acute phase protein, CRP, may be to active Mo and that the process may require a CRP-binding serum component.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3038302

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  C-reactive protein and hepatocellular carcinoma: analysis of its relationships to tumor factors.

Authors:  Brian I Carr; Hikmet Akkiz; Vito Guerra; Oguz Üsküdar; Sedef Kuran; Ümit Karaoğullarından; Salih Tokmak; Tuğsan Ballı; Abdulalh Ülkü; Tolga Akçam; Anıl Delik; Burcu Arslan; Figen Doran; Kendal Yalçın; Engin Altntaş; Ayşegül Özakyol; Mehmet Yücesoy; Halil İbrahim Bahçeci; Kamil Yalçın Polat; Nazım Ekinci; Halis Şimşek; Necat Örmeci; Abdulalh Sonsuz; Mehmet Demir; Murat Kılıç; Ahmet Uygun; Ali Demir; Sezai Yilmaz; Yaman Tokat
Journal:  Clin Pract (Lond)       Date:  2018

Review 2.  C-reactive protein, inflammation, and innate immunity.

Authors:  R F Mortensen
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

3.  Degradation of rat C-reactive protein by macrophages.

Authors:  A Nagpurkar; D Hunt; C Y Yang; S Mookerjea
Journal:  Biochem J       Date:  1993-10-01       Impact factor: 3.857

4.  Therapeutic effects of a synthetic peptide of C-reactive protein in pre-clinical tumor models.

Authors:  B P Barna; D A Eppstein; M J Thomassen; J J Nestor; T Ho; S V Medendorp; S D Deodhar
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

Review 5.  Associations between physical activity and susceptibility to cancer: possible mechanisms.

Authors:  R J Shephard; P N Shek
Journal:  Sports Med       Date:  1998-11       Impact factor: 11.136

6.  Monocyte tumoricidal activity and tumor necrosis factor production in patients with malignant brain tumors.

Authors:  B P Barna; L R Rogers; M J Thomassen; G H Barnett; M L Estes
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 7.  A hypothesis resolving the apparently disparate activities of native and altered forms of human C-reactive protein.

Authors:  M J Shields
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

8.  Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma.

Authors:  Hikmet Akkiz; Brian I Carr; Harika G Bag; Ümit Karaoğullarından; Kendal Yalçın; Nazim Ekin; Ayşegül Özakyol; Engin Altıntaş; Hatice Y Balaban; Halis Şimşek; Ahmet Uyanıkoğlu; Ayhan Balkan; Sedef Kuran; Oğuz Üsküdar; Yakup Ülger; Burak Güney; Anil Delik
Journal:  Int J Clin Pract       Date:  2020-12-12       Impact factor: 2.503

9.  Mutations of C-reactive protein (CRP) -286 SNP, APC and p53 in colorectal cancer: implication for a CRP-Wnt crosstalk.

Authors:  Hai-Xiang Su; Hai-Hong Zhou; Ming-Yu Wang; Jin Cheng; Shi-Chao Zhang; Feng Hui; Xue-Zhong Chen; Shan-Hui Liu; Qin-Jiang Liu; Zi-Jiang Zhu; Qing-Rong Hu; Yi Wu; Shang-Rong Ji
Journal:  PLoS One       Date:  2014-07-15       Impact factor: 3.240

Review 10.  C-Reactive Protein and Cancer: Interpreting the Differential Bioactivities of Its Pentameric and Monomeric, Modified Isoforms.

Authors:  Lawrence A Potempa; Ibraheem M Rajab; Margaret E Olson; Peter C Hart
Journal:  Front Immunol       Date:  2021-09-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.